News Posts List
MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information
12/28/2018
The Memorial Sloan Kettering Cancer Center (MSKCC) risk stratification model in advanced renal cell carcinoma (RCC) currently used in clinical practice stratifies patients into risk groups of favorable, intermediate, and poor.
Cancer research legend urges patients to get multiple opinions
12/27/2018
National Cancer Institute Chief of Surgery Steven Rosenberg recommends seeking out multiple professional opinions to confirm a diagnosis and to figure out what your best options are.
Clinicopathological Features and Survival Data of Localized Renal Masses in Young Adults
12/26/2018
According to a study that was done by the Asian Pacific Journal of Cancer Prevention, the overall survival rate of young adults (ages 18-40 years old) with localized renal masses is 93.8%.
Optimizing Combinations Next Challenge in mRCC
12/21/2018
As the treatment paradigm for metastatic renal cell carcinoma (mRCC) continues to evolve, combination therapy is likely to be an important part of the future, said Bradley G. Somer, MD.
Future Directions for RCC Research
12/20/2018
Dr. Brian Rini and Dr. David McDermott explain whatâs next in kidney cancer research.
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
12/20/2018
Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic factors for overall survival (OS) in RCC patients with BMs.
Immediate Surgery No Help in Metastatic RCC
12/14/2018
Treating metastatic kidney cancer with immediate cytoreductive nephrectomy (CN) did not ward off disease progression, the randomized SURTIME trial confirmed.
Life threatening toxicities of chemotherapies and immunomodulating medications
12/14/2018
Life threatening toxicities of chemotherapies and immunosuppressants can occur with varying frequency depending on the agent suspected and underlying patient risk factors. It is important for clinicians to remember that these medications can be the cause or contributor to many important complications that occur in the ICU.
Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies
12/14/2018
Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse.
Overview of Renal Cell Cancer
12/13/2018
Symptoms, risk factors and diagnosis of Kidney (Renal Cell) Cancer.
News Feed